Production (Stage)
Fulcrum Therapeutics, Inc.
FULC
$6.78
-$0.05-0.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 80.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 80.00M | -- |
| Cost of Revenue | 13.40M | 11.71M | 14.64M | 17.26M | 19.77M |
| Gross Profit | -13.40M | -11.71M | -14.64M | 62.74M | -19.77M |
| SG&A Expenses | 7.00M | 7.72M | 8.42M | 10.25M | 10.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.40M | 19.43M | 23.06M | 27.51M | 29.83M |
| Operating Income | -20.40M | -19.43M | -23.06M | 52.49M | -29.83M |
| Income Before Tax | -17.66M | -16.57M | -21.70M | 55.41M | -26.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.66M | -16.57M | -21.70M | 55.41M | -26.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.66M | -16.57M | -21.70M | 55.41M | -26.87M |
| EBIT | -20.40M | -19.43M | -23.06M | 52.49M | -29.83M |
| EBITDA | -20.05M | -19.06M | -22.69M | 52.87M | -29.36M |
| EPS Basic | -0.28 | -0.31 | -0.35 | 0.89 | -0.43 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.20 | 0.56 | -0.27 |
| EPS Diluted | -0.28 | -0.31 | -0.35 | 0.87 | -0.43 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.20 | 0.54 | -0.27 |
| Average Basic Shares Outstanding | 62.48M | 53.95M | 62.41M | 62.21M | 61.98M |
| Average Diluted Shares Outstanding | 62.48M | 53.95M | 62.41M | 63.59M | 61.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |